LLY

968.75

+5.03%↑

JNJ

186.89

+0.32%↑

UNH

320.81

-1.02%↓

NVS

126.45

+0.13%↑

ABT

125.6

-0.47%↓

LLY

968.75

+5.03%↑

JNJ

186.89

+0.32%↑

UNH

320.81

-1.02%↓

NVS

126.45

+0.13%↑

ABT

125.6

-0.47%↓

LLY

968.75

+5.03%↑

JNJ

186.89

+0.32%↑

UNH

320.81

-1.02%↓

NVS

126.45

+0.13%↑

ABT

125.6

-0.47%↓

LLY

968.75

+5.03%↑

JNJ

186.89

+0.32%↑

UNH

320.81

-1.02%↓

NVS

126.45

+0.13%↑

ABT

125.6

-0.47%↓

LLY

968.75

+5.03%↑

JNJ

186.89

+0.32%↑

UNH

320.81

-1.02%↓

NVS

126.45

+0.13%↑

ABT

125.6

-0.47%↓

Search

West Pharmaceutical Services Inc

Aperta

SettoreSettore sanitario

274.06 1.45

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

270.13

Massimo

276.38

Metriche Chiave

By Trading Economics

Entrata

8.2M

140M

Vendite

38M

804M

P/E

Media del settore

41.51

77.256

EPS

1.96

Rendimento da dividendi

0.3

Margine di Profitto

17.406

Dipendenti

10,600

EBITDA

17M

215M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+28.26% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.30%

2.33%

Prossima data del Dividendo

19 nov 2025

Prossima data del' Ex Dividendo

12 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

361M

20B

Apertura precedente

272.61

Chiusura precedente

274.06

Notizie sul Sentiment di mercato

By Acuity

50%

50%

161 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

West Pharmaceutical Services Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 nov 2025, 21:36 UTC

Utili

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 nov 2025, 21:22 UTC

Utili

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 nov 2025, 00:00 UTC

Discorsi di Mercato

India Inflation Poised to Hit New Low -- Market Talk

9 nov 2025, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 nov 2025, 23:35 UTC

Discorsi di Mercato

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 nov 2025, 21:05 UTC

Utili

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 nov 2025, 21:04 UTC

Utili

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 nov 2025, 21:03 UTC

Utili

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 nov 2025, 20:49 UTC

Utili

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 nov 2025, 20:49 UTC

Utili

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 nov 2025, 20:45 UTC

Utili

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 nov 2025, 20:45 UTC

Utili

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 nov 2025, 20:42 UTC

Utili

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 nov 2025, 20:42 UTC

Utili

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 nov 2025, 20:41 UTC

Utili

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 nov 2025, 20:41 UTC

Utili

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 nov 2025, 20:39 UTC

Utili

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 nov 2025, 20:39 UTC

Utili

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 nov 2025, 20:38 UTC

Utili

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 nov 2025, 20:38 UTC

Utili

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 nov 2025, 20:38 UTC

Utili

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 nov 2025, 13:10 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 03:50 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Utili

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Utili

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q EPS $9.89 >CSU.T

Confronto tra pari

Modifica del prezzo

West Pharmaceutical Services Inc Previsione

Obiettivo di Prezzo

By TipRanks

28.26% in crescita

Previsioni per 12 mesi

Media 347.63 USD  28.26%

Alto 375 USD

Basso 311 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per West Pharmaceutical Services Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

9

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

213.26 / 219.27Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

161 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat